<DOC>
	<DOCNO>NCT01328002</DOCNO>
	<brief_summary>The purpose study evaluate safety , tolerability , efficacy , pharmacokinetics milnacipran pediatric patient age 13 17 year primary fibromyalgia .</brief_summary>
	<brief_title>Safety Efficacy Milnacipran Pediatric Patients With Primary Fibromyalgia</brief_title>
	<detailed_description>- 8 week open-label milnacipran period - Followed randomization 8-weeks double blind treatment period eligible patient</detailed_description>
	<mesh_term>Fibromyalgia</mesh_term>
	<mesh_term>Myofascial Pain Syndromes</mesh_term>
	<mesh_term>Milnacipran</mesh_term>
	<criteria>Diagnosis primary fibromyalgia 1317 year age Severe psychiatric illness Severe renal impairment Evidence active liver disease Pregnant breastfeeding Significant risk suicidality Unable , unwilling unadvisable discontinue prohibit medication</criteria>
	<gender>All</gender>
	<minimum_age>13 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>August 2012</verification_date>
	<keyword>Fibromyalgia</keyword>
	<keyword>Pediatric Fibromyalgia</keyword>
	<keyword>Adolescent Fibromyalgia</keyword>
	<keyword>milnacipran</keyword>
	<keyword>Savella</keyword>
	<keyword>loss therapeutic response</keyword>
	<keyword>Forest Research Institute</keyword>
	<keyword>Pain</keyword>
	<keyword>Fatigue</keyword>
	<keyword>Serotonin Norepinephrine Reuptake Inhibitors</keyword>
	<keyword>Randomized Withdrawal</keyword>
</DOC>